Biography and Research Information
OverviewAI-generated summary
Randal S. Shelton's research focuses on understanding and manipulating the tumor microenvironment to enhance cancer therapies. His recent work investigates the synergistic effects of oncolytic viruses and immune checkpoint blockade in models of hepatocellular carcinoma and pancreatic cancer. Shelton also explores novel therapeutic targets for multiple myeloma, specifically the role of PHF19 inhibition.
Further investigations include the reprogramming of the pancreatic tumor microenvironment through alloantigen-expressing virotherapy to improve immunotherapy response and tumor rejection. His work also examines the modulation of immune cell infiltration by live attenuated vaccines in hepatocellular carcinoma models to enhance survival. Additionally, Shelton has studied the cellular mechanisms of kidney injury, specifically the role of Endonuclease G in cisplatin-induced damage.
Metrics
- h-index: 4
- Publications: 20
- Citations: 68
Selected Publications
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025)
-
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)
-
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)
-
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)
-
Endonuclease G (EndoG) Inhibits DNase I-Mediated Apoptosis and DNA Repair in Kidney Tubular Epithelial Cells During Cisplatin Injury (2023)
-
Comprehensive Risk Assessment of Carbon Nanotubes Used for Agricultural Applications (2022)
-
PHF19 inhibition as a therapeutic target in multiple myeloma (2021)
Collaboration Network
Top Collaborators
Alexei G. Basnakian
University of Arkansas for Medical Sciences
6 shared publications
In database
- Comprehensive Risk Assessment of Carbon Nanotubes Used for Agricultural Applications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Endonuclease G (EndoG) Inhibits DNase I-Mediated Apoptosis and DNA Repair in Kidney Tubular Epithelial Cells During Cisplatin Injury
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Showing 5 of 6 shared publications
Mulu Z. Tesfay
University of Arkansas for Medical Sciences
6 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 6 shared publications
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
6 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 6 shared publications
Aleksandra Cios
Winthrop Rockefeller Foundation (US)
6 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 6 shared publications
Camila Simões
University of Arkansas for Medical Sciences
6 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 6 shared publications
Steven R. Post
University of Arkansas for Medical Sciences
6 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 6 shared publications
Martin J. Cannon
University of Arkansas for Medical Sciences
5 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Bahaa Mustafa
Winthrop Rockefeller Foundation
5 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Jean Christopher Chamcheu
Southern University and Agricultural and Mechanical College (US)
4 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Omeed Moaven
Louisiana State University Health Sciences Center New Orleans (US)
4 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Thomas J. Kelly
University of Arkansas for Medical Sciences
3 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Bolni Marius Nagalo
University of Maryland, Baltimore
3 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Alicja Urbaniak
University of Arkansas for Medical Sciences
3 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Isabelle R. Miousse
Winthrop Rockefeller Foundation
3 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Chiswili Chabu
University of Missouri (US)
3 shared publications
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Similar Researchers
Based on overlapping research topics
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
John P. Lee
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Disease Mechanisms Research
Eric R. Siegel
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Rang Govindarajan
University of Arkansas for Medical Sciences
Pancreatic and Hepatic Oncology Research
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Jillian Hackney
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Disease Mechanisms Research